Semaglutide News and Research

Latest Semaglutide News and Research

KFF Health News' 'What the Health?': New Year, new Congress, new health agenda

The new, GOP-led, 119th Congress and President-elect Donald Trump have big legislative plans for the year — which mostly don't include health policy. But health is likely to play an important supporting role in efforts to renew tax cuts, revise immigration policies, and alter trade — if only to help pay for some Republican initiatives.

9 Jan 2025

Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

9 Jan 2025

UK's drug payment disclosure system fails to protect patients and public trust

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is failing to protect patients and public trust, according to a new analysis led by researchers at the University of Bath, UK and Lund University, Sweden published in BMJ Evidence-Based Medicine.

9 Jan 2025

GLP-1 drugs linked to fewer post-surgical complications in diabetic patients

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery, according to a large study led by investigators at Weill Cornell Medicine, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

6 Jan 2025

Do GLP-1 receptor agonists increase the risk of suicide in patients?

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal behaviors in high-risk populations.

6 Jan 2025

New Year, new approach to weight loss: Almost three quarters of UK women are considering using GLP-1s in 2025

As 2024 draws to a close, the new year ushers in the opportunity to set new goals for the year ahead. While weight-loss and fitness are staples of New Year resolutions they are commonly known to be the unsustainable resolutions that don't continue past January.

3 Jan 2025

Lithocholic acid enhances health and lifespan, mimicking calorie restriction

Lithocholic acid (LCA), a metabolite induced by calorie restriction (CR), activates AMPK and mimics anti-aging benefits. A recent study highlights LCA's role in improving muscle performance, glucose tolerance, and lifespan in aged organisms.

1 Jan 2025

The power of the mind in weight loss and long-term success

2024 can easily be dubbed the year of Ozempic, but the negative effects of the now Holywood famous drug can heavily outweigh the positives in the long run. Really, what many of us need is the power of our mind to lose weight and keep it off for good.

22 Dec 2024

Understanding metformin's mechanism in reducing blood sugar

Millions of people take metformin, a Type 2 diabetes medication that lowers blood sugar. The "wonder drug" has also been shown to slow cancer growth, improve COVID outcomes and reduce inflammation. But until now, scientists have been unable to determine how, exactly, the drug works.

18 Dec 2024

Study finds racial and ethnic disparities in the use of obesity-management drugs

Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications to lower their weight compared with whites, new research suggests.

18 Dec 2024

Nutraceuticals: exploring potential benefits and challenges of an unregulated healthcare frontier

Nutraceuticals offer potential health benefits, from migraine relief to cognitive support, but safety and regulatory issues must be addressed for effective use.

18 Dec 2024

How a duty to spend wisely on worker benefits could loosen PBMs’ grip on drug prices

Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market. Her job, as a policy advocate at drugmaker Johnson & Johnson, was to tell patient and physician groups about the PBMs' role in high drug prices.

18 Dec 2024

Danish studies find increased risk of optic nerve damage with diabetes medicine

Two independent studies from the University of Southern Denmark (SDU) show that patients with type 2 diabetes who are treated with the drug Ozempic have an increased risk of developing damage to the optic nerve of the eye, which can lead to severe and permanent loss of vision.

16 Dec 2024